1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,900 | 13,200 | 27.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.06. | Spyre reports results from early stage TL1A antibody trials | 2 | Seeking Alpha | ||
| 17.06. | Spyre reports positive results for anti-TL1A antibodies in trials | 2 | Investing.com | ||
| 17.06. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.06. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts | 377 | PR Newswire | SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up;... ► Artikel lesen | |
| 03.06. | Guggenheim reiterates Buy rating on Spyre stock citing pipeline progress | 2 | Investing.com | ||
| 02.06. | Spyre Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.05. | Spyre Therapeutics GAAP EPS of -$0.60 | 1 | Seeking Alpha | ||
| 08.05. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.05. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | 91 | PR Newswire | On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts... ► Artikel lesen | |
| 08.05. | Spyre Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 05.05. | Spyre Presents Promising SPY001 IBD Data And Combination Therapy Results At DDW 2025 | 1 | RTTNews | ||
| 28.03. | BTIG maintains Spyre stock Buy rating, $70 target | 15 | Investing.com | ||
| 27.03. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody | 158 | PR Newswire | Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience... ► Artikel lesen | |
| 18.03. | Wolfe Research initiates Spyre stock with Outperform rating | 3 | Investing.com | ||
| 27.02. | Spyre Therapeutics GAAP EPS of -$0.81 beats by $0.21 | 2 | Seeking Alpha | ||
| 27.02. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | 413 | PR Newswire | Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million... ► Artikel lesen | |
| 27.02. | Spyre Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 27.02. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.01. | Spyre Therapeutics, Inc.: Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts | 191 | PR Newswire | Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025
Phase 1 interim results expected for SPY003, an extended... ► Artikel lesen | |
| 13.01. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 9,550 | +1,06 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody | Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 17,600 | -4,35 % | Palvella Therapeutics Inc.: Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% | Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 15,300 | -1,92 % | Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside | ||
| JOUNCE THERAPEUTICS | - | - | IBM's Red Hat acquires stealth Israeli startup Jounce for $20M to bolster AI cloud stack | ||
| LENZ THERAPEUTICS | 30,110 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| TOURMALINE BIO | 16,550 | -0,96 % | Tourmaline Bio, Inc.: Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease | - Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo... ► Artikel lesen | |
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? |
SPYRE THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,29 % bei einem Aktienkurs von 13,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.